UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

~~Exchange~~Date ~~Act~~of Report (Date of ~~1934~~earliest event reported): June 20, 2025

Date of Report (Date of earliest event reported): April 2, 2025

THC Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Nevada

000-55994

26-0164981

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

203 S. Church Street

1600 Sky Park Dr # 215

Medford, OR

97504

(Address of principal executive offices)

(Zip Code)

~~Jacksboro, TX 76458~~(833)-420-8428

(~~Address~~Registrant’s oftelephone ~~Principal~~number, ~~Executive~~including ~~Offices~~area code)

~~(972)~~Not ~~217-4080~~applicable

Telephone Number

11700 W. Charleston Blvd.

#73

Las Vegas, NV 89135

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 51.0201. ~~Departure~~Entry ofinto ~~Directors~~a orMaterial ~~Certain~~Definitive ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Agreement.

On ~~April~~June 220, 2025, ~~the majority shareholder of the~~ THC Therapeutics, Inc. (the “Company”), ~~voted~~entered tointo ~~remove~~a ~~Brandon~~Share ~~Romanek~~Exchange ~~from~~Agreement (the ~~Board~~“Share ofExchange ~~Directors~~Agreement”) ofwhereby the Company shall acquire 100% of The Headquarters Group, Inc., ~~Further~~an Oregon corporation, onand ~~that~~its ~~same~~related ~~day~~subsidiaries, ~~the~~in ~~remaining~~exchange ~~Board~~in exchange for 11,007 shares of ~~Directors~~newly ~~removed~~created ~~Mr.~~Series ~~Romanek~~D ~~from~~Preferred ~~any~~Stock ~~and~~(the ~~all~~“Series ~~positions~~D ~~held~~Preferred”) atof the Company.

Item 2.01 Completion of Acquisition or Disposition of Assets.

~~SIGNATURES~~On June 20, 2025 the “Company closed the Share Exchange Agreement and acquired 100% of The Headquarters Group, Inc., an Oregon corporation, and its related subsidiaries, in exchange for 11,007 shares of newly created Series D Preferred stock of the Company.

~~Pursuant~~The toforegoing ~~the~~description ~~requirements~~ of the ~~Securities~~Share ~~Exchange~~Ecchange ~~Act~~Agreement ofdoes ~~1934,~~not ~~the~~purport ~~registrant~~to ~~has~~be ~~duly~~complete ~~caused~~and ~~this~~is ~~report~~qualified toin beits ~~signed~~entirety onby ~~its~~reference ~~behalf~~to bythe full text of the ~~undersigned~~Agreement, ~~hereunto~~a ~~duly~~copy ~~authorized~~of which is attached as Exhibit 10.1 to this Form 8-K.

	THC Therapeutics, Inc.
Dated: April 8, 2025	By:	/s/ Scott Cox
		Scott Cox
		Chief Executive Officer

Item 3.02. Unregistered Sales of Equity Securities.

The disclosure in Item 1.01 and 1.02 above is incorporated by reference into this Item 3.02.

Item 7.01. Regulation FD Disclosure.

On June 24, 2025, the Company issued a press release regarding completion of the transaction contemplated by the Shares Exchange Agreement as described in Item 1.01 and 2.01 above. A copy of the Press Release issued by the Company is attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated by reference solely for purposes of this Item 7.01 disclosure.

Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
3.1		Certificate of Designation for Series D Preferred Stock dated June 21, 2025
10.1		Acquisition Agreement dated June 20,2025
99.1		Press Release dated June 20, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THC Therapeutics, Inc.

Dated: June 26, 2025	By:	/s/ Scott Cox
		Scott Cox
		Interim Chief Executive Officer

Filing Compare · THC Therapeutics, Inc.